Item 2.02 Results of Operations and Financial Condition.

As part of its updated corporate investor presentation, as described below, Spero Therapeutics, Inc. (the "Company") disclosed that its cash, cash equivalents and marketable securities as of December 31, 2022 was approximately $109.0 million. The following information should be considered in connection with this preliminary result: The Company's audited, consolidated financial statements as of December 31, 2022, are not yet available. Accordingly, the information presented above reflects the Company's preliminary estimate, subject to the completion of the Company's financial closing procedures and the annual audit of its financial statements by its auditors. As a result, this preliminary estimate may differ from the actual results that will be reflected in the Company's audited, consolidated financial statements for the fiscal year ended December 31, 2022 when they are completed and publicly disclosed. This preliminary estimate may change, and that change may be material. The Company's independent registered public accountants have not audited, reviewed or performed any procedures with respect to such preliminary estimate and accordingly do not express an opinion or any other form of assurance with respect thereto.

Item 7.01. Regulation FD Disclosure.

On January 9, 2023, the Company updated its investor presentation (the "Investor Presentation"), which the Company expects to use in connection with general corporate presentations and will be made available on the Company's website or distributed by the Company in hardcopy or electronic form.

A copy of the Investor Presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report"). The Investor Presentation is current as of January 9, 2023, and the Company disclaims any obligation to update the Investor Presentation after such date.

In accordance with General Instruction B.2 on Form 8-K, except as set forth under Item 8.01 below, the information set forth in this Item 7.01 and the Investor Presentation is "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended.

Item 8.01 Other Events.

Certain portions of the Investor Presentation are attached as Exhibit 99.2 to this Current Report and are filed with this Current Report.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits

Exhibit
Number       Description

99.1           Investor Presentation of Spero Therapeutics, Inc. dated January 9,
             2023.

99.2           Excerpts from Investor Presentation of Spero Therapeutics, Inc.
             dated January 9, 2023.

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document).




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses